MedTrace Logo

Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension

NCT02179008 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 184

Last updated 2018-04-18

No results posted yet for this study

Summary

The purpose of this study is to investigate the safety and efficacy of five concentrations of DE-117 ophthalmic solution.

Conditions

Interventions

DRUG

DE-117 Low Dose ophthalmic solution

Low Dose DE-117 ophthalmic solution

DRUG

DE-117 Low/Middle Dose ophthalmic solution

Low/Middle Dose DE-117

DRUG

DE-117 Middle Dose ophthalmic solution

Middle Dose DE-117

DRUG

DE-117 Middle/High Dose ophthalmic solution

Middle/High Dose DE-117

DRUG

DE-117 High Dose ophthalmic solution

High Dose DE-117

DRUG

latanoprost ophthalmic solution 0.005%

0.005% latanoprost

Sponsors & Collaborators

  • Santen Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-01-31
Completion
2015-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02179008 on ClinicalTrials.gov